HCV Advocate Logo HCV Advocate Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
News Revie
Conference Reports
News Articles
Hcv Advocate Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp
 
 
Media Releases

 

Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp: Drug Safety Communication Audience: Oncological and nephrological healthcare professionals and patients

Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp: Drug Safety Communication Audience: Oncological and nephrological healthcare professionals and patients

[Posted 02/16/2010] FDA and Amgen notified healthcare professionals and patients that all ESAs must be used under a REMS risk management program. As part of the risk management program, a Medication Guide explaining the risks and benefits of ESAs must be provided to all patients receiving an ESA. Under the ESA APPRISE Oncology program, Amgen will ensure that only those hospitals and healthcare professionals who have enrolled and completed training in the program will prescribe and dispense ESAs to patients with cancer. Amgen is also required to oversee and monitor the program to ensure that hospitals and healthcare professionals are fully compliant with all aspects of the program. FDA is requiring a REMS because studies show that ESAs can increase the risk of tumor growth and shorten survival in patients with cancer who use these products. Studies also show that ESAs can increase the risk of heart attack, heart failure, stroke or blood clots in patients who use these drugs for other conditions.

[02/16/2010 - Drug Safety Communication1 - FDA]

[01/2010 - Epogen Prescribing Information2 - Amgen]

[01/2010 - Aranesp (darbepoetin alfa) Prescribing Information3 - Amgen]

Previous MedWatch alerts: [07/31/20084]

 

 

 

Back to top



About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Recursos en Espaņol | Home

Hepatitis C Support Project

(C) 2010. Hepatitis C Support Project

Medical  Writers' Circle
Fact Sheets

 
5